---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-009752"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2021-08-02T23:59:59+00:00"
generated_at: "2026-06-29T23:43:24.572381+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q2 net loss $78.5M; UKONIQ revenue $1.5M; U2 PDUFA March 2022

## Summary
- Net loss $78.5M for Q2 2021, up from $52.9M in Q2 2020; ex-stock comp net loss ~$62.2M.
- UKONIQ net revenue $1.5M in Q2 (total $2.3M since Feb 2021 launch); product revenue zero year ago.
- FDA accepted BLA/sNDA for U2 (ublituximab+UKONIQ) in CLL/SLL; PDUFA goal date March 25, 2022.
- Cash $456.2M at June 30, 2021; company expects to fund operations into 2023.
- Plan to submit BLA for ublituximab in relapsing MS in Q3 2021 based on positive Phase 3 results.

## SEC filing metadata
- accession: 0001558370-21-009752
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2021-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837021009752/0001558370-21-009752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837021009752/tgtx-20210802x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-009752
- JSON: https://secwatch.observer/filing/0001558370-21-009752.json
- Plain text: https://secwatch.observer/filing/0001558370-21-009752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.